Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 35
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Serotonergic mechanisms involved in antidepressant-like responses evoked by GLT-1 blockade in rat infralimbic cortex

  • Gasull-Camós, Júlia
  • Martínez-Torres, Sara
  • Tarrés-Gatius, Mireia
  • Ozaita Mintegui, Andrés, 1969-
  • Artigas, Francesc
  • Castañé Forn, Anna
Novel fast-acting antidepressant strategies, such as ketamine and deep brain stimulation, enhance glutamatergic neurotransmission in medial prefrontal cortex (mPFC) regions via AMPA receptor (AMPA-R) activation. We recently reported that the regionally-selective blockade of the glial glutamate transporter-1 (GLT-1) by dihydrokainic acid (DHK) microinfusion in rat infralimbic cortex (IL), the most ventral part of the mPFC, evoked immediate (10 min) antidepressant-like responses, which involved AMPA-R activation and were associated to increased serotonin (5-hydroxytryptamine, 5-HT) release. Given the reciprocal connectivity between the mPFC and the serotonergic dorsal raphe nucleus (DR), here we examined the serotoninergic mechanisms involved in the reported antidepressant-like responses of DHK microinfusion. First, we show that antidepressant-like responses evoked by IL application of DHK and citalopram are mediated by local 5-HT1A receptors (5-HT1A-R), since they are cancelled by previous IL WAY100635 microinfusion. Second, IL DHK microinfusion increases excitatory inputs onto DR, as shown by an increased glutamate and 5-HT release in DR and by a selective increase of c-Fos expression in DR 5-HT neurons, not occurring in putative GABAergic neurons. This view is also supported by an increased 5-HT release in ventral hippocampus following IL DHK microinfusion. Interestingly, antidepressant-like responses evoked by IL DHK lasted for 2¿h and could be prolonged for up to 24¿h by attenuating self-inhibitory effects via 5-HT1A autoreceptors. In contrast, the antidepressant-like effects of S-AMPA microinfusion in IL were short-lasting. Together, our results further support a prominent role of the IL-DR pathway and of ascending 5-HT pathways in mediating antidepressant-like responses evoked by glutamatergic mechanisms., This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2015-68346 and BES2013-063241 to J.G-C; BFU2015-68568-P to A.O.) co-financed by European Regional Development Fund; Generalitat de Catalunya (CERCA Programme; 2014-SGR798, 2016FI-B00285 to M.T-G, 2016 FI-B00531 to S.M-T and ICREA Acadèmia to A.O.); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission

  • Riga, Maurizio
  • Sánchez, Connie
  • Celada, Pau
  • Artigas, Francesc
The antidepressant vortioxetine is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine occupies all targets at high therapeutic doses and only SERT and 5-HT3-R at low doses. Vortioxetine increases extracellular monoamine concentrations in rat forebrain more than selective serotonin reuptake inhibitors (SSRI) and shows pro-cognitive activity in preclinical models. Given its high affinity for 5-HT3-R (Ki = 3.7 nM), selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT3-R blockade. Here we assessed vortioxetine effect on pyramidal neuron activity and extracellular 5-HT concentration using in vivo extracellular recordings of rat medial prefrontal cortex (mPFC) pyramidal neurons and microdialysis in mPFC and ventral hippocampus (vHPC). Vortioxetine, but not escitalopram, increased pyramidal neuron discharge in mPFC. This effect was prevented by SR57227A (5-HT3-R agonist) and was mimicked by ondansetron (5-HT3-R antagonist) and by escitalopram/ondansetron combinations. In microdialysis experiments, ondansetron augmented the 5-HT-enhancing effect of escitalopram in mPFC and vHPC. Local ondansetron in vHPC augmented escitalopram effect, indicating the participation of intrinsic mechanisms. Since 5-HT neurons express GABAB receptors, we examined their putative involvement in controlling 5-HT release after 5-HT3-R blockade. Co-perfusion of baclofen (but not muscimol) reversed the increased 5-HT levels produced by vortioxetine and escitalopram/ondansetron combinations in vHPC. The present results suggest that vortioxetine increases glutamatergic and serotonergic neurotransmission in rat forebrain by blocking 5-HT3 receptors in GABA interneurons., This work was supported by a grant from Lundbeck A/S and by grants SAF 2012-35183 and SAF 2015-68346-P from the Spanish Ministry of Economy and Competitiveness, co-financed by European Regional Development Fund (ERDF) and grant PI12/00156 (Instituto de Salud Carlos III, co-financed by European Regional Development Fund (ERDF). Support from the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Generalitat de Catalunya Grup de Recerca Consolidat, (2014SGR798) is also acknowledged. FA and PC are PI and co-PI from a grant from Lundbeck A/S to examine the mechanism of action of vortioxetine. FA has also received lecture and consultation fees from Lundbeck A/S and is scientific advisor to Neurolixis. CS is a Lundbeck A/S employee., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Expression of Serotonin2C Receptors in Pyramidal and GABAergic Neurons of Rat Prefrontal Cortex. A Comparison with Striatum

  • Santana, Noemí
  • Artigas, Francesc
The prefrontal cortex (PFC) is enriched in several serotonin receptors, including 5-HT1A-R, 5- HT2A-R and 5-HT3-R. These receptors modulate PFC activity due to their expression in large neuronal populations (5-HT1A-R, 5-HT2A-R) or in selected GABAergic populations (5-HT3-R). They are also relevant for antidepressant and antipsychotic drug action. Less is known about the localization of 5-HT2C-R, for which atypical antipsychotics show high affinity. Here we report on the cellular distribution of 5-HT2C-R in rat PFC and striatum, using double in situ hybridization histochemistry. In PFC, 5-HT2C-R are expressed in pyramidal (VGLUT1-positive) and GABAergic (GAD-positive) neurons, including parvalbumin-positive neurons. There is a marked dorsoventral gradient in the proportion of VGLUT1-positive cells expressing 5-HT2C-R, (9% in cingulate cortex, 61% in tenia tecta and 66% in piriform cortex), less marked for GABAergic neurons (13-27%). There is also a laminar gradient, with more cells expressing 5-HT2C-R in deep (V-VI) than in intermediate (II-III) layers. In common with 5-HT3-R, layer I GABAergic cells express 5-HT2C-R. The proportion of 5-HT2C-R-expressing striatal neurons was 23% (dorsolateral caudate-putamen), 37% (ventromedial caudate-putamen), 53% (nucleus accumbens-core) and 49% (nucleus accumbens-shell). These results help to better understand the serotonergic modulation of PFC-based networks, including basal ganglia circuits, and atypical antipsychotic drug action., Study supported by grants SAF 2012-35183 and SAF-2015-68346-P from the Spanish Ministry of Economy and Competitiveness, co-financed by European Regional Development Fund (ERDF), and by the Generalitat de Catalunya (2014SGR798). Support from the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) is also acknowledged. N.S. is supported by CIBERSAM., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Subchronic vortioxetine treatment –but not escitalopram- enhances pyramidal neuron activity in the rat prefrontal cortex, Subchronic vortioxetine enhances cortical activity

  • Riga, Maurizio
  • Teruel-Martí, Vicent
  • Sánchez, Connie
  • Celada, Pau
  • Artigas, Francesc
Vortioxetine (VOR) is a multimodal antidepressant drug. VOR is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin transporter (SERT) inhibitor. VOR shows pro-cognitive activity in animal models and beneficial effects on cognitive dysfunction in major depressive patients. Here we compared the effects of 14-day treatments with VOR and escitalopram (ESC, selective serotonin reuptake inhibitor) on neuronal activity in the medial prefrontal cortex (mPFC). Ten groups of rats (5 standard, 5 depleted of 5-HT with p-chlorophenylalanine-pCPA-, used as model of cognitive impairment) were fed with control food or with two doses of VOR-containing food. Four groups were implanted with minipumps delivering vehicle or ESC 10 mg/kg·day s.c. The two VOR doses enable occupation by VOR of SERT+5-HT3-R and all targets, respectively, and correspond to SERT occupancies in patients treated with 5 and 20 VOR mg/day, respectively. Putative pyramidal neurons (n=985) were recorded extracellularly in the mPFC of anesthetized rats. Sub-chronic VOR administration (but not ESC) significantly increased neuronal discharge in standard and 5-HT-depleted conditions, with a greater effect of the low VOR dose in standard rats. VOR increased neuronal discharge in infralimbic (IL) and prelimbic (PrL) cortices. Hence, oral VOR doses evoking SERT occupancies similar to those in treated patients increase mPFC neuronal discharge. The effect in 5-HT-depleted rats cannot be explained by an antagonist action of VOR at 5-HT3-R and suggests a non-canonical interaction of VOR with 5-HT3-R. These effects may underlie the superior pro-cognitive efficacy of VOR compared with SSRIs in animal models, Supported by Lundbeck A/S and grants: SAF2015-68346-P (Spanish Ministry of Economy and Competitiveness, co-financed by European Regional Development Fund (ERDF)) and PI12/00156 (Instituto de Salud Carlos III, co-financed by European Regional Development Fund (ERDF)). Support from the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Generalitat de Catalunya Grup de Recerca Consolidat, 2014SGR798 is also acknowledged, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder

  • Artigas, Francesc
  • Bortolozzi, Analía
Major depressive disorder (MDD) is a severe psychiatric syndrome with very-high socioeconomic impact worldwide (Global Burden of Disease Study 2013 Collaborators, 2015). This is attributable to three main factors: (i) MDD is a highly prevalent disorder in the general population, (ii) depressive episodes have long duration and occur during active periods of adult life, resulting in very large labor costs, and (iii) standard MDD treatments have limited efficacy, leaving a high percentage of patients with incomplete responses and poor quality of life, thus increasing suicide risk (Rush et al, 2006)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The antipsychotic drug brexpiprazole reverses phencyclidine-induced disruptions of thalamocortical networks

  • van den Munkhof, Hanna
  • Arnt, Jørn
  • Celada, Pau
  • Artigas, Francesc
Brexpiprazole (BREX), a recently approved antipsychotic drug in the US and Canada, improves cognitive dysfunction in animal models, by still largely unknown mechanisms. BREX is a partial agonist at 5‐HT1A and D2 receptors and antagonist at α1B- and α2C-adrenergic and 5-HT2A receptors all with a similar potency. The NMDA receptor antagonist phencyclidine (PCP), used as pharmacological model of schizophrenia, activates thalamocortical networks and decreases low frequency oscillations (LFO; <4 Hz). These effects are reversed by antipsychotics. Here we assessed the ability of BREX to reverse PCP-induced hyperactivity of thalamocortical circuits, and the involvement of 5-HT1A receptors in its therapeutic action. BREX reversed PCP-induced neuronal activation at a lower dose in centromedial/mediodorsal thalamic nuclei (CM/MD; 0.5 mg/kg) than in pyramidal medial prefrontal cortex neurons (mPFC, 2 mg/kg), perhaps due to antagonism at α1B-adrenoceptors, abundantly expressed in the thalamus. Conversely, a cumulative 0.5 mg/kg dose reversed a PCP-induced LFO decrease in mPFC but not in CM/MD. BREX reduced LFO in both areas, yet with a different dose-response, and moderately excited mPFC neurons. The latter effect was reversed by the 5-HT1A receptor antagonist WAY-100635. Thus, BREX partly antagonizes PCP-induced thalamocortical hyperactivity, differentially in mPFC versus CM/MD. This regional selectivity may be related to the differential expression of α1B-, α2C-adrenergic and 5-HT2A receptors in both regions and/or different neuronal types. Furthermore, the pro-cognitive properties of BREX may be related to the 5-HT1A receptor-mediated increase in mPFC pyramidal neuron activity. Overall, the present data provide new insight on the brain elements involved in BREX's therapeutic actions., Work supported by a contract Grant from Lundbeck and grants SAF2015-68346-P (MINECO, FEDER EU) and (PI1200156 and PI1600287) Instituto de Salud Carlos III (Spanish Ministry of Economy and Competitiveness), co-financed by ERDF (European Regional Development Fund), “A way to build Europe”. The contribution of the following funds is also acknowledged: 2014SGR 798 (Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya), CERCA Programme/Generalitat de Catalunya; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Opposite control of mesocortical and mesoaccumbal dopamine pathways by serotonin2B receptor blockade: Involvement of medial prefrontal cortex serotonin1A receptors

  • Devroyea, Céline
  • Haddjeri, Nasser
  • Cathala, Adeline
  • Rovera, Renaud
  • Drago, Filippo
  • Piazza, Pier Vincenzo
  • Artigas, Francesc
  • Spampinato, Umberto
Recent studies have shown that serotonin2B receptor (5-HT2BR) antagonists exert opposite facilitatory and inhibitory effects on dopamine (DA) release in the medial prefrontal cortex (mPFC) and the nucleus accumbens (NAc), respectively, thereby leading to the proposal that these compounds could provide an interesting pharmacological tool for treating schizophrenia. Although the mechanisms underlying these effects remain unknown, several data in the literature suggest that 5-HT1ARs located into the mPFC could participate in this interaction. The present study, using in vivo microdialysis and electrophysiological recordings in rats, assessed this hypothesis by means of two selective 5-HT1AR (WAY 100635) and 5-HT2BR (RS 127445) antagonists. WAY 100635, administered either subcutaneously (0.16 mg/kg, s.c) or locally into the mPFC (0.1 μM), blocked the changes of mPFC and NAc DA release induced by the intraperitoneal administration of RS 127445 (0.16 mg/kg, i.p.). The administration of RS 127445 (0.16 mg/kg, i.p.) increased both dorsal raphe nucleus (DRN) 5-HT neuron firing rate and 5-HT outflow in the mPFC. Likewise, mPFC 5-HT outflow was increased following the intra-DRN injection of RS 127445 (0.032 μg/0.2 μl). Finally, intra-DRN injection of RS 127445 increased and decreased DA outflow in the mPFC and the NAc, respectively, these effects being reversed by the intra-mPFC perfusion of WAY 100635. These results demonstrate the existence of a functional interplay between mPFC 5-HT1ARs and DRN 5-HT2BRs in the control of the DA mesocorticolimbic system, and highlight the clinical interest of this interaction, as both receptors represent an important pharmacological target for the treatment of schizophrenia., This work was supported by grants from the Institut National de la Recherche et de la Santé (INSERM), Bordeaux University, the Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM and grant SAF2015-68346-P (MINECO-FEDER). C. Devroye was a fellowship recipient from the International Ph.D. program in Neuropharmacology, University of Catania Medical School, Catania, Italy, during the course of this study., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Temporally dissociable effects of ketamine on neuronal discharge and gamma oscillations in rat thalamo-cortical networks

  • Amat Foraster, María
  • Jensen, Anders A.
  • Plath, Niels
  • Herrik, Kjartan F.
  • Celada, Pau
  • Artigas, Francesc
A partial account of the present study was presented at the 29th Congress of the European College of Neuropsychopharmacology, Vienna 2016 and at the Society for Neuroscience 2017 Annual Meeting., [Background] Sub-anesthetic doses of the non-competitive N-methyl-d-aspartate receptor (NMDA-R) antagonist ketamine evoke transient psychotomimetic effects, followed by persistent antidepressant effects in treatment-resistant depressed patients and rodents through still poorly understood mechanisms. Since phencyclidine (PCP) disinhibits thalamo-cortical networks by blocking NMDA-Rs on GABAergic neurons of the reticular thalamic nucleus (RtN), we examined ketamine's actions in the same areas., [Methods] Single units and local field potentials were recorded in chloral hydrate anesthetized male Wistar rats. The effects of cumulative ketamine doses (0.25–5 mg/kg, i.v.) on neuronal discharge and oscillatory activity were examined in RtN, mediodorsal and centromedial (MD/CM) thalamic nuclei, and layer VI of the medial prefrontal cortex (mPFC)., [Results] Ketamine (1, 2 and 5 mg/kg, i.v.) significantly decreased the discharge of MD/CM, RtN and layer VI mPFC pyramidal neurons. Simultaneously, ketamine decreased the power of low frequency oscillations in all areas examined and increased gamma oscillations in mPFC and MD/CM. Lower ketamine doses (0.25 and 0.5 mg/kg, i.v.) were ineffective., [Conclusions] As observed for PCP, ketamine markedly inhibited the activity of RtN neurons. However, unlike PCP, this effect did not translate into a disinhibition of MD/CM and mPFC excitatory neurons, possibly due to a more potent and simultaneous blockade of NMDA-Rs by ketamine in MD/CM and mPFC neurons. Hence, the present in vivo results show that ketamine evokes an early transient inhibition of neuronal discharge in thalamo-cortical networks, following its rapid pharmacokinetics, which is likely associated to its psychotomimetic effects. The prolonged increase in gamma oscillations may underlie its antidepressant action., The work leading to these results has received funding from Lundbeck A/S, the Innovation Fund Denmark (4135-00084B), SAF2015-68346-P (Spanish Ministry of Economy and Competitiveness, co-financed by European Regional Development Fund (ERDF)) and (PI12/00156 and PI16/00287)Instituto de Salud Carlos III (Spanish Ministry of Economy and Competitiveness, co-financed by European Regional Development Fund (ERDF)). Support from the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) (Instituto de Salud Carlos III) and Generalitat de Catalunya Grup de Recerca Consolidat, 2017SGR717 is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Serotonergic mechanisms involved in antidepressant-like responses evoked by GLT-1 blockade in rat infralimbic cortex

  • Gasull-Camós, Júlia
  • Martínez-Torres, Sara
  • Tarrés-Gatius, Mireia
  • Ozaita, Andrés
  • Artigas, Francesc
  • Castañé, Anna
Novel fast-acting antidepressant strategies, such as ketamine and deep brain stimulation, enhance glutamatergic neurotransmission in medial prefrontal cortex (mPFC) regions via AMPA receptor (AMPA-R) activation. We recently reported that the regionally-selective blockade of the glial glutamate transporter-1 (GLT-1) by dihydrokainic acid (DHK) microinfusion in rat infralimbic cortex (IL), the most ventral part of the mPFC, evoked immediate (10 min) antidepressant-like responses, which involved AMPA-R activation and were associated to increased serotonin (5-hydroxytryptamine, 5-HT) release. Given the reciprocal connectivity between the mPFC and the serotonergic dorsal raphe nucleus (DR), here we examined the serotoninergic mechanisms involved in the reported antidepressant-like responses of DHK microinfusion. First, we show that antidepressant-like responses evoked by IL application of DHK and citalopram are mediated by local 5-HT1A receptors (5-HT1A-R), since they are cancelled by previous IL WAY100635 microinfusion. Second, IL DHK microinfusion increases excitatory inputs onto DR, as shown by an increased glutamate and 5-HT release in DR and by a selective increase of c-Fos expression in DR 5-HT neurons, not occurring in putative GABAergic neurons. This view is also supported by an increased 5-HT release in ventral hippocampus following IL DHK microinfusion. Interestingly, antidepressant-like responses evoked by IL DHK lasted for 2 h and could be prolonged for up to 24 h by attenuating self-inhibitory effects via 5-HT1A autoreceptors. In contrast, the antidepressant-like effects of S-AMPA microinfusion in IL were short-lasting. Together, our results further support a prominent role of the IL–DR pathway and of ascending 5-HT pathways in mediating antidepressant-like responses evoked by glutamatergic mechanisms., This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2015-68346 and BES2013-063241 to J.G-C; BFU2015-68568-P to A.O.) co-financed by European Regional Development Fund; Generalitat de Catalunya (CERCA Programme; 2014-SGR798, 2016FI-B00285 to M.T-G, 2016 FI-B00531 to S.M-T and ICREA Acadèmia to A.O.); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Effects of hallucinogens on neuronal activity

  • Lladó-Pelfort, Laia
  • Celada, Pau
  • Riga, Maurizio
  • Troyano-Rodriguez, Eva
  • Santana, Noemí
  • Artigas, Francesc
Hallucinogens evoke sensory, perceptual, affective, and cognitive effects that may be useful to understand the neurobiological basis of mood and psychotic disorders. The present chapter reviews preclinical research carried out in recent years in order to better understand the action of psychotomimetic agents such as the noncompetitive NMDA receptor (NMDA-R) antagonists and serotonergic hallucinogens. Our studies have focused on the mechanisms through which these agents alter cortical activity. Noncompetitive NMDA-R antagonists, such as phencyclidine (PCP) and MK-801 (dizocilpine), as well as the serotonergic hallucinogens DOI and 5-MeO-DMT, produce similar effects on cellular and population activity in prefrontal cortex (PFC); these effects include alterations of pyramidal neuron discharge (with an overall increase in firing), as well as a marked attenuation of the low frequency oscillations (0.2–4 Hz) to which neuronal discharge is coupled in anesthetized rodents. PCP increases c-fos expression in excitatory neurons from various cortical and subcortical areas, particularly the thalamus. This effect of PCP involves the preferential blockade of NMDA-R on GABAergic neurons of the reticular nucleus of the thalamus, which provides feedforward inhibition to the rest of thalamic nuclei. It is still unknown whether serotonergic hallucinogens also affect thalamocortical networks. However, when examined, similar alterations in other cortical areas, such as the primary visual cortex (V1), have been observed, suggesting that these agents affect cortical activity in sensory and associative areas. Interestingly, the disruption of PFC activity induced by PCP, DOI and 5-MeO-DMT is reversed by classical and atypical antipsychotic drugs. This effect suggests a possible link between the mechanisms underlying the disruption of perception by multiple classes of hallucinogenic agents and the therapeutic efficacy of antipsychotic agents., Supported by the Innovative Medicines Initiative Joint Undertaking (IMI) under Grant Agreement N° 115008 (NEWMEDS). IMI is a public–private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations. Support from the following grants is also acknowledged: SAF 2015-68346-P (Ministry of Economy and Competitiveness and European Regional Development Fund), PI09/1245 and PI12/00156 (PN de I+D+I 2008–2011, ISCIII-Subdireccion General de Evaluación y Fomento de la Investigación cofinanced by the European Regional Development Fund. “Una manera de hacer Europa”) and Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM (P82, 11INT3). Support from the Generalitat de Catalunya (SGR20093) is also acknowledged. MR is recipient of a IDIBAPS fellowship., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies

  • Artigas, Francesc
  • Bortolozzi, Analía
  • Celada, Pau
Major depressive disorder (MDD) is a severe psychiatric syndrome with high prevalence and socioeconomic impact. Current antidepressant treatments are based on the blockade of serotonin (5-hydroxytryptamine, 5-HT) and/or noradrenaline transporters. These drugs show slow onset of clinical action and limited efficacy, partly due to the activation of physiological negative feed-back mechanisms operating through autoreceptors (5-HT1A, 5-HT1B, α2-adrenoceptors) and postsynaptic receptors (e.g., 5-HT3). As a result, clinically-relevant doses of reuptake inhibitors increase extracellular (active) 5-HT concentrations in the midbrain raphe nuclei but not in forebrain, as indicated by rodent microdialysis studies and by PET-scan studies in primate/human brain. The prevention of these self-inhibitory mechanisms by antagonists of the above receptors augments preclinical and clinical antidepressant effects. Hence, the mixed ß-adrenoceptor/5-HT1A antagonist pindolol accelerated, and in some cases enhanced, the clinical action of selective serotonin reuptake inhibitors (SSRI). This strategy has been incorporated into two new multi-target antidepressant drugs, vilazodone and vortioxetine, which combine 5-HT reuptake inhibition and partial agonism at 5-HT1A receptors. Vortioxetine shows also high affinity for other 5-HT receptors, including excitatory 5-HT3 receptors located in cortical and hippocampal GABA interneurons. 5-HT3 receptor blockade by vortioxetine enhances pyramidal neuron activity in prefrontal cortex as well as cortical and hippocampal 5-HT release. It is still too soon to know whether these new antidepressants will represent a real advance over existing drugs in the real world. However, their development opened the way to future antidepressant drugs based on the prevention of local and distal self-inhibitory mechanisms attenuating monoamine activity., Support from the following grants is acknowledged: grants SAF2015-68346-P, SAF2016-75797-R and Retos-Colaboración Subprogram RTC-2014-2812-1, Ministry of Economy, Industry and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE; grants PI12/00156, PI13/01390 and PI16/00287, Instituto de Salud Carlos III, co-financed by European Regional Development Fund (ERDF), UE, “A way to build Europe”; the Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (Grup de Recerca Consolidat 2014SGR798)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies

  • Artigas, Francesc
  • Celada, Pau
  • Bortolozzi, Analía
In the second part we focus on two treatment strategies that may overcome the main limitations of current antidepressant drugs. First, we review the experimental and clinical evidence supporting the use of glutamatergic drugs as fast-acting antidepressants. Secondly, we review the involvement of microRNAs (miRNAs) in the pathophysiology of major depressive disorder (MDD) and the use of small RNAs (e.g.., small interfering RNAs or siRNAs) to knockdown genes in monoaminergic and non-monoaminergic neurons and induce antidepressant-like responses in experimental animals. The development of glutamatergic agents is a promising venue for antidepressant drug development, given the antidepressant properties of the non-competitive NMDA receptor antagonist ketamine. Its unique properties appear to result from the activation of AMPA receptors by a metabolite [(2 S,6 S;2 R,6 R)-hydroxynorketamine (HNK)] and mTOR signaling. These effects increase synaptogenesis in prefrontal cortical pyramidal neurons and enhance serotonergic neurotransmission via descending inputs to the raphe nuclei. This view is supported by the cancellation of ketamine's antidepressant-like effects by inhibition of serotonin synthesis. We also review existing evidence supporting the involvement of miRNAs in MDD and the preclinical use of RNA interference (RNAi) strategies to target genes involved in antidepressant response. Many miRNAs have been associated to MDD, some of which e.g., miR-135 targets genes involved in antidepressant actions. Likewise, SSRI-conjugated siRNA evokes faster and/or more effective antidepressant-like responses. Intranasal application of sertraline-conjugated siRNAs directed to 5-HT1A receptors and SERT evoked much faster changes of pre- and postsynaptic antidepressant markers than those produced by fluoxetine., Support from the following grants is acknowledged: SAF2015-68346-P, SAF2016-75797-R and Retos-Colaboración Subprogram RTC-2015–3309-1, MINECO co-financed by European Regional Development Fund - ERDF), UE (Ministry of Economy and Competitiveness and European Regional Development Fund), PI12/00156, PI16/00287 and PI13/01390 (Instituto de Salud Carlos III, co-financed by ERDF, "A way to build Europe"), and Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM. Support from the Generalitat de Catalunya (2014SGR798 and 2017SGR717) is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Laminar and cellular distribution of monoamine receptors in rat medial prefrontal cortex

  • Santana, Noemí
  • Artigas, Francesc
The prefrontal cortex (PFC) is deeply involved in higher brain functions, many of which are altered in psychiatric conditions. The PFC exerts a top-down control of most cortical and subcortical areas through descending pathways and is densely innervated by axons emerging from the brainstem monoamine cell groups, namely, the dorsal and median raphe nuclei (DR and MnR, respectively), the ventral tegmental area and the locus coeruleus (LC). In turn, the activity of these cell groups is tightly controlled by afferent pathways arising from layer V PFC pyramidal neurons. The reciprocal connectivity between PFC and monoamine cell groups is of interest to study the pathophysiology and treatment of severe psychiatric disorders, such as major depression and schizophrenia, inasmuch as antidepressant and antipsychotic drugs target monoamine receptors/transporters expressed in these areas. Here we review previous reports examining the presence of monoamine receptors in pyramidal and GABAergic neurons of the PFC using double in situ hybridization. Additionally, we present new data on the quantitative layer distribution (layers I, II–III, V, and VI) of monoamine receptor-expressing cells in the cingulate (Cg), prelimbic (PrL) and infralimbic (IL) subfields of the medial PFC (mPFC). The receptors examined include serotonin 5-HT1A, 5-HT2A, 5-HT2C, and 5-HT3, dopamine D1 and D2 receptors, and α1A-, α1B-, and α1D-adrenoceptors. With the exception of 5-HT3 receptors, selectively expressed by layers I–III GABA interneurons, the rest of monoamine receptors are widely expressed by pyramidal and GABAergic neurons in intermediate and deep layers of mPFC (5-HT2C receptors are also expressed in layer I). This complex distribution suggests that monoamines may modulate the communications between PFC and cortical/subcortical areas through the activation of receptors expressed by neurons in intermediate (e.g., 5-HT1A, 5-HT2A, α1D-adrenoceptors, dopamine D1 receptors) and deep layers (e.g., 5-HT1A, 5-HT2A, α1A-adrenoceptors, dopamine D2 receptors), respectively. Overall, these data provide a detailed framework to better understand the role of monoamines in the processing of cognitive and emotional signals by the PFC. Likewise, they may be helpful to characterize brain circuits relevant for the therapeutic action of antidepressant and antipsychotic drugs and to improve their therapeutic action, overcoming the limitations of current drugs., This work was supported by the Spanish Ministry of Economy and Competitiveness (grant number SAF2015-68346), co-financed by European Regional Development Fund (ERDF), EU; Generalitat de Catalunya (grant number 2014-SGR798) and Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Differential patterns of subcortical activity evoked by glial GLT-1 blockade in prelimbic and infralimbic cortex: Relationship to antidepressant-like effects in rats

  • Gasull-Camós, Júlia
  • Soto-Montenegro, María L.
  • Casquero-Veiga, Marta
  • Desco, Manuel
  • Artigas, Francesc
  • Castañé, Anna
[Background] Glutamatergic neurotransmission has emerged as a novel target in antidepressant drug development, with a critical role of the ventral anterior cingulate cortex. We recently reported that blockade of the astrocytic glutamate transporter GLT-1 with dihydrokainic acid in infralimbic cortex (rodent equivalent of ventral anterior cingulate cortex), but not in the adjacent prelimbic cortex, evoked robust antidepressant-like effects through α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor activation and increased serotonin release. [Methods] 2-deoxy-2-[18F]-fluoro-D-glucose-positron emission tomography and computed tomography in 36 male Wistar rats microinfused bilaterally in prelimbic cortex or infralimbic cortex with dihydrokainic acid or vehicle. [Results] Dihydrokainic acid microinfusion in infralimbic cortex and prelimbic cortex evoked dramatically different regional patterns of subcortical activity. In infralimbic cortex, dihydrokainic acid selectively affected midbrain areas, whereas in prelimbic cortex it affected the basal ganglia, the thalamus, and both superior and inferior colliculi. [Conclusions] These results highlight the differential connectivity of infralimbic and prelimbic cortex with subcortical brain regions and support the involvement of infralimbic cortex-midbrain pathway in the antidepressant-like effects of dihydrokainic acid., This work was supported by Spanish Ministry of Economy and Competitiveness grants (SAF2012-35183, SAF2015-68346, ISCIII-FIS PI14/00860 and CPII14/00005, and BES2013-063241 J.GC.) cofinanced by European Regional Development Fund, Generalitat de Catalunya (2014-SGR798), Comunidad de Madrid (BRADE-CM S2013/ICE-2958), Mapfre foundation, Alicia Koplowitz Foundation (FAK16/01), and Centro de Investigación Biomédica en Red de Salud Mental., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glial GLT-1 blockade in infralimbic cortex as a new strategy to evoke rapid antidepressant-like effects in rats

  • Gasull-Camós, Júlia
  • Tarrés-Gatius, Mireia
  • Artigas, Francesc
  • Castañé, Anna
Ketamine and deep brain stimulation produce rapid antidepressant effects in humans and rodents. An increased AMPA receptor (AMPA-R) signaling in medial prefrontal cortex (mPFC) has been suggested to mediate these responses. However, little research has addressed the direct effects of enhancing glutamate tone or AMPA-R stimulation in mPFC subdivisions. The current study investigates the behavioral and neurochemical consequences of glutamate transporter-1 (GLT-1) blockade or s-AMPA microinfusion in the infralimbic (IL) and prelimbic (PrL) cortex. Owing to the connectivity between the mPFC and raphe nuclei, the role of serotonin is also explored. The bilateral microinfusion of the depolarizing agent veratridine into IL -but not PrL- of rats evoked immediate antidepressant-like responses. The same regional selectivity was observed after microinfusion of dihydrokainic acid (DHK), a selective inhibitor of GLT-1, present in astrocytes. The DHK-evoked antidepressant-like responses appear to be mediated by an AMPA-R-driven enhancement of serotonergic activity, as (i) they were prevented by NBQX 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt) and mimicked by s-AMPA; (ii) DHK and s-AMPA elevated similarly extracellular glutamate in IL and PrL, although extracellular 5-HT and c-fos expression in the midbrain dorsal raphe increased only when these agents were applied in IL; and (iii) DHK antidepressant-like responses were prevented by 5-HT synthesis inhibition and mimicked by citalopram microinfusion in IL. These results indicate that an acute increase of glutamatergic neurotransmission selectively in IL triggers immediate antidepressant-like responses in rats, likely mediated by the activation of IL–raphe pathways, which then results in a fast increase of serotonergic activity., This work was supported by the Spanish Ministry of Economy and Competitiveness (grant numbers SAF2012-35183; SAF2015-68346; and BES2013-063241 to JG-C), co-financed by European Regional Development Fund (ERDF); Generalitat de Catalunya (grant number 2014-SGR798 and 2016FI-B00285 to MT-G) and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Modulation of thalamo-cortical activity by ketamine in rats

  • Amat Foraster, María
  • Celada, Pau
  • Jensen, Anders A.
  • Plath, Niels
  • Artigas, Francesc
  • Herrik, Kjartan F.
Trabajo presentado en el Neuroscience 2017, celebrado en Washington del 11 al 15 de noviembre de 2017, Background: Faster and more effective antidepressant treatments are needed to overcome the limitations of current monoamine-based drugs. Interestingly, sub-anesthetic doses of ketamine have been shown to produce immediate and persistent antidepressant effects. However, ketamine use is limited by its psychotomimetic properties and abuse potential. Therefore, we investigated the actions of ketamine on thalamo-cortical networks to increase our knowledge of the brain circuitry affected by ketamine and thus elucidate the mechanism underlying its antidepressant effects, ultimately leading to the development of novel antidepressants without ketamine’s side effects. Methods: We conducted single unit and local field potentials recordings in the mediodorsal (MD), centromedial (CM) and reticular (RtN) nucleus of the thalamus, as well as in the medial prefrontal cortex (mPFC) of freely-moving (except RtN) and chloral hydrate anesthetized male Wistar rats, using microelectrode arrays and glass electrodes. The acute effects of ketamine (3 and 10 mg/kg s.c. in freely-moving rats; 1, 2 and 5 mg/kg i.v. in anesthetized rats) on the firing properties and oscillations of these neuronal populations were assessed. The effects of ketamine at 24 hours post administration were also examined in the freely-moving recordings. Results: In anesthetized rats, ketamine acutely decreased the discharge rate of RtN, MD/CM and layer VI mPFC neurons projecting to the thalamus. In addition, ketamine modulated oscillatory rhythms, reducing the power of low frequency oscillations in anesthetized rats and increasing gamma oscillations in both freely-moving and anesthetized rats. Moreover, increases in high frequency oscillations were observed in freely-moving rats. These effects were short-lasting since they were not present at 24h post administration. Further analysis is needed to characterize the changes observed on the firing characteristics in freely-moving rats. Conclusion: This study provides insights on the neurobiological changes that occur in the thalamo-cortical networks by ketamine both acutely and at 24 hours post administration. Ongoing efforts to characterize the firing rates of these neuronal populations in freely-moving rats will be crucial to understand the implications of the observed effects by ketamine in the thalamo-cortical networks of anesthetized rats., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Murine model of depression: astroglial glutamate transporter knockdown in infralimbic cortex induces a depressive phenotype

  • Fullana, Neus
  • Ruiz-Bronchal, Esther
  • Ferrés-Coy, Albert
  • Bortolozzi, Analía
  • Artigas, Francesc
Trabajo presentado en el Neuroscience 2017, celebrado en Washington del 11 al 15 de noviembre de 2017, Emerging evidence suggests that dysregulations of glutamatergic neurotransmission in prefrontal cortex are involved in the pathophysiology of depression. Astrocytes regulate excitatory neurotransmission by removing synaptic glutamate via GLAST and GLT-1 transporters. We demonstrated that unilateral knockdown of GLAST and GLT-1 in mouse infralimbic (IL) cortex induced by the local micro-infusion of small interfering RNAs (siRNA) targeting either transporter evoked a depressive-like phenotype. Conversely, intra-prelimbic (Prl) cortex microinfusion of both siRNAs did not affect behavioral responses despite comparable reductions of GLAST and GLT-1-1 expression in both PFC subdivisions. Downregulation of GLAST and GLT-1 remained diminished for at least 3 day and recovered 7 days post-administration. The depressive-like phenotype induced by reducing GLT-1 and GLAST expression in IL may be due to a hypoactive serotonergic (5-HT) system since it was reversed by the antidepressant drug citalopram. Likewise, microdialysis experiments revealed that siRNA-treated mice exhibited a reduced basal 5-HT release in the dorsal raphe nucleus (DRN) compared with controls, and a similar effect of veratridine in both experimental groups, indicating a similar intracellular 5-HT content. Further, local infusion of the GABAA receptor antagonist bicuculline increased DRN-5-HT release more markedly in siRNA-treated mice, suggesting a greater inhibition of 5-HT neurons via GABAA receptors. However, local downregulation of both transporters in PrL did not alter baseline 5-HT in DRN not the effect of bicuculline on 5-HT release. Taken together, these observations suggest that 1) an alteration of astroglial glutamate uptake in ventral PFC regions (IL) evokes downstream changes in 5-HT function, associated to a depressive-like phenotype in mice, and 2) the regional specificity of the effect suggests a differential functional connectivity between PrL/IL and DRN 5-HT neurons. In addition, this potential new model of MDD shows several physio pathological markers observed in patients: reduced expression of GFAP, a smaller number of astrocytes in mPFC, as well as a decreased BDNF expression in mPFC and the hippocampal formation, which is highly and significantly correlated with the degree of glutamate transporter knockdown in IL, indicating a direct relationship between both processes. Overall, these findings improve our understanding of the pathophysiology of depression and could help to identify novel targets in antidepressant drug development, since this potential new MDD model mimics many of the functional and molecular alterations observed in MDD patients., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Role of the infralimbic cortex in depression: Functional connectivity and behavioral phenotypes

  • Gasull-Camós, Júlia
Tesis llevada a cabo para conseguir el grado de Doctor por la Universidadde Barcelona.--2017-12-15.--Excelente cum laude, La depresión mayor es una de las principales causas de incapacidad en el mundo, con elevado impacto socioeconómico debido principalmente a su alta prevalencia y la larga duración de los episodios depresivos. Además, los fármacos antidepresivos más utilizados (inhibidores selectivos de recaptación de serotonina -5-HT- o SSRI; e inhibidores dobles de la recaptación de 5-HT y noradrenalina (NA) o SNRI) poseen dos grandes inconvenientes: baja eficacia y lentitud de acción. En la última década, se han propuesto dos nuevas estrategias antidepresivas que podrían superar estas limitaciones: la estimulación cerebral profunda (DBS) de zonas ventrales de la corteza prefrontal (CPF) y la administración sistémica del antagonista no competitivo de los receptores NMDA de glutamato, ketamina. A diferencia de los fármacos clásicos, DBS y ketamina producen efectos antidepresivos rápidos. Estudios de neuroimagen han mostrado alteraciones metabólicas en zonas ventrales de la CPF medial en pacientes con depresión. También se ha descrito una reducción del volumen en esta área, que estaría asociada a una disminución del número de células gliales. En ratas, la CPF medial se divide principalmente la corteza prelímibica (PrL, dorsal) e infralímbica (IL, ventral). Estas áreas presentan diferente conectividad con áreas subcorticales del cerebro, lo cual sugiere que podrían tener diferentes funciones. Así, bajo la hipótesis de trabajo que PrL y IL contribuyen de forma diferente en la regulación de los estados de ánimo, hemos estudiado las consecuencias comportamentales, neuroquímicas y de circuitería, tras aumentar la neurotransmisión glutamatérgica en ambas áreas. Para ello, hemos bloqueado selectivamente el principal transportador glial de glutamato, GLT-1., Nuestros resultados muestran que el aumento de glutamato en IL, pero no en PrL, produce efectos antidepresivos inmediatos en ratas. Estos efectos requieren la activación de receptores AMPA y están mediados por 5-HT. De manera interesante, la activación de las cortezas PrL y IL produce diferentes patrones de actividad subcortical. Concretamente, tras la activación de la corteza IL se producen cambios importantes en la zona del cerebro medio, donde se encuentra el núcleo dorsal del rafe (DR). Estás alteraciones metabólicas estarían implicadas en los efectos antidepresivos, dado los cambios observados en la neurotransmisión serotoninérgica. Además, el aumento de la concentración de glutamato en la corteza IL produce un aumento de actividad en neuronas del DR, así como un aumento de liberación de serotonina local en DR y áreas de proyección (como IL e hipocampo). Los efectos antidepresivos observados dependen de los receptores post-sinápticos de serotonina 5-HTlA localizados en la corteza IL. Finalmente, hemos observado que los auto­receptores 5-HTlA del DR limitan el mantenimiento de la respuesta antidepresiva a las 24h. En resumen, nuestros resultados indican que un aumento de la neurotransmisión glutamatérgica específicamente en la corteza IL produce efectos antidepresivos, que estarían mediados por una activación del circuito IL - DR., Aquesta tesis doctoral ha estat finançada a través dels següents projectes: 1. Papel de la corteza infralímbica en depresión: conectividad funciuonal y desarrollo de un modelo animal. Amb codi: SAF2012-35183. Finançada per el Ministerio de Economía y Competitividad. Cofinançada per FEDER. 2. Alteraciones de la corteza infralímbica en depresión: mecanismo de acción de nuevas estrategias antidepresivas. Amb codi: SAF2015-68346. Finançada per el Ministerio de Economía y Competitividad. Cofinançada per FEDER. 3. Grup d’Investigació consolidat, Neuroquímica i Neurofarmacologia. Amb codi 2014SGR798. Finançat per la Generalitat de Catalunya. I ha sigut realitzada amb la següent beca predoctoral: Ayudas para contratos predoctorales para la formación de doctores (FPI). Amb codi: BES2013-063241. Finançada per el Ministerio de Economía y Competitividad., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for Depression

  • Fullana, Neus
  • Ferrés-Coy, Albert
  • Ortega, Jorge E.
  • Ruiz-Bronchal, Esther
  • Paz, Verónica
  • Meana, J. Javier
  • Artigas, Francesc
  • Bortolozzi, Analía
Current pharmacological treatments for major depressive disorder (MDD) are severely compromised by both slow action and limited efficacy. RNAi strategies have been used to evoke antidepressant-like effects faster than classical drugs. Using small interfering RNA (siRNA), we herein show that TASK3 potassium channel knockdown in monoamine neurons induces antidepressant-like responses in mice. TASK3-siRNAs were conjugated to cell-specific ligands, sertraline (Ser) or reboxetine (Reb), to promote their selective accumulation in serotonin (5-HT) and norepinephrine (NE) neurons, respectively, after intranasal delivery. Following neuronal internalization of conjugated TASK3-siRNAs, reduced TASK3 mRNA and protein levels were found in the brainstem 5-HT and NE cell groups. Moreover, Ser-TASK3-siRNA induced robust antidepressant-like behaviors, enhanced the hippocampal plasticity, and potentiated the fluoxetine-induced increase on extracellular 5-HT. Similar responses, yet of lower magnitude, were detected for Reb-TASK3-siRNA. These findings provide substantial support for TASK3 as a potential target, and RNAi-based strategies as a novel therapeutic approach to treat MDD., This work was supported by the following grants: SAF2015-68346-P (F.A.); SAF2013-48586-R (J.M.); SAF2016-75797-R (A.B.); Retos-Colaboración Subprograms RTC-2014-2812-1 and RTC-2015-3309-1 (A.B.); Ministry of Economy and Competitiveness (MINECO)—European Regional Development Fund (ERDF), UE; PI13/01390, Instituto de Salud Carlos III co-financed by ERDF (A.B.); IT616-13 Basque Government—ERDF (J.M.); 20003 NARSAD Independent Investigator (A.B.); and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). CERCA Programme/Generalitat de Catalunya is also acknowledged. M.N.F. and A.F-C. are recipients of a fellowship from the Spanish Ministry of Education, Culture and Sport., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Regionally selective knockdown of astroglial glutamate transporters in infralimbic cortex induces a depressive phenotype in mice

  • Fullana, Neus
  • Ruiz-Bronchal, Esther
  • Ferrés-Coy, Albert
  • Juárez-Escoto, Elena
  • Artigas, Francesc
Elevation of energy metabolism and disturbance of astrocyte number/function in the ventral anterior cingulate cortex (vACC) contributes to the pathophysiology of major depressive disorder (MDD). Functional hyperactivity of vACC may result from reduced astrocytic glutamate uptake and increased neuronal excitation. Here we tested this hypothesis by knocking‐down astrocytic glutamate transporter GLAST/GLT‐1 expression in mouse infralimbic (IL, rodent equivalent of vACC) or prelimbic (PrL) cortices using RNAi strategies. Unilateral siRNA (small interfering RNA) microinfusion targeting GLAST or GLT‐1 in mouse IL induced a moderate (20–30%) and long‐lasting (7 days) decrease in their expression. Intra‐IL GLAST‐/GLT‐1 siRNA microinfusion reduced the number of glial fibrillary acidic protein (GFAP)‐positive and glutamine synthetase (GS)‐positive astrocytes and evoked a depressive‐like phenotype reversed by citalopram and ketamine. Intra‐IL GLAST or GLT‐1 knockdown markedly reduced serotonin (5‐HT) release in the dorsal raphe nucleus (DR) and induced an overall reduction of brain‐derived neurotrophic factor (BDNF) expression in ipsilateral and contralateral hemispheres. Egr‐1 (early growth response protein‐1) labeling suggests that both siRNAs enhance the GABAergic tone onto DR 5‐HT neurons, leading to an overall decrease of 5‐HT function, likely related to the widespread reduction on BDNF expression. Conversely, similar reductions of GLAST and GLT‐1 expression in PrL did not induce a depressive‐like phenotype. These results suggest that a focal glial change in IL translates into global change of brain activity by virtue of the descending projections from IL to DR and the subsequent attenuation of serotonergic function in forebrain, an effect perhaps related to the varied symptomatology of MDD., This study was supported by the Spanish Ministry of Economy and Competitiveness, SAF2015‐68346‐P (F.A.) and SAF2016‐75797‐R (A.B.); Retos‐Colaboración Subprogram RTC‐2015‐3309‐1 (A.B.) cofinanced by the European Regional Development Fund “A way to build Europe”. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and CERCA Programme/Generalitat de Catalunya is also acknowledged. N.F. is a recipient of a fellowship from Spanish Ministry of Education, Culture, and Sport., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Serotonin2B receptors in the rat dorsal raphe nucleus exert a GABA-mediated tonic inhibitory control on serotonin neurons

  • Cathala, Adeline
  • Devroyea, Céline
  • Drutel, Guillaume
  • Revest, Jean-Michel
  • Artigas, Francesc
  • Spampinato, Umberto
The central serotonin2B receptor (5-HT2BR) is a well-established modulator of dopamine (DA) neuron activity in the rodent brain. Recent studies in rats have shown that the effect of 5-HT2BR antagonists on accumbal and medial prefrontal cortex (mPFC) DA outflow results from a primary action in the dorsal raphe nucleus (DRN), where they activate 5-HT neurons innervating the mPFC. Although the mechanisms underlying this interaction remain largely unknown, data in the literature suggest the involvement of DRN GABAergic interneurons in the control of 5-HT activity. The present study examined this hypothesis using in vivo (intracerebral microdialysis) and in vitro (immunohistochemistry coupled to reverse transcription-polymerase chain reaction) experimental approaches in rats. Intraperitoneal (0.16 mg/kg) or intra-DRN (1 μM) administration of the selective 5-HT2BR antagonist RS 127445 increased 5-HT outflow in both the DRN and the mPFC, these effects being prevented by the intra-DRN perfusion of the GABAA antagonist bicuculline (100 μM), as well as by the subcutaneous (0.16 mg/kg) or the intra-DRN (0.1 μM) administration of the selective 5-HT1AR antagonist WAY 100635. The increase in DRN 5-HT outflow induced by the intra-DRN administration of the selective 5-HT reuptake inhibitor citalopram (0.1 μM) was potentiated by the intra-DRN administration (0.5 μM) of RS 127445 only in the absence of bicuculline perfusion. Finally, in vitro experiments revealed the presence of the 5-HT2BR mRNA on DRN GABAergic interneurons. Altogether, these results show that, in the rat DRN, 5-HT2BRs are located on GABAergic interneurons, and exert a tonic inhibitory control on 5-HT neurons innervating the mPFC., This study was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM) and Bordeaux University and by grant SAF2015-68346-P from the Spanish Ministry of Economy and Competitiveness., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In vivo glutamate clearance defects in a mouse model of Lafora disease

  • Muñoz-Ballester, Carmen
  • Santana, N.
  • Pérez-Jiménez, Eva
  • Viana, Rosa
  • Artigas, Francesc
  • Sanz, Pascual
9 páginas, 5 figuras, 1 tabla, Lafora disease (LD) is a fatal rare neurodegenerative disorder characterized by epilepsy, neurodegeneration and insoluble polyglucosan accumulation in brain and other peripheral tissues. Although in the last two decades we have increased our knowledge on the molecular basis underlying the pathophysiology of LD, only a small part of the research in LD has paid attention to the mechanisms triggering one of the most lethal features of the disease: epilepsy. Recent studies in our laboratory suggested that a dysfunction in the activity of the mouse astrocytic glutamate transporter 1 (GLT-1) could contribute to epilepsy in LD. In this work, we present new in vivo evidence of a GLT-1 dysfunction, contributing to increased levels of extracellular glutamate in the hippocampus of a mouse model of Lafora disease (Epm2b-/-, lacking the E3-ubiquitin ligase malin). According to our results, Epm2b-/- mice showed an increased neuronal activity, as assessed by c-fos expression, in the hippocampus, an area directly correlated to epileptogenesis. This brain area presented lesser ability to remove synaptic glutamate after local GLT-1 blockade with dihydrokainate (DHK), in comparison to Epm2b+/+ animals, suggesting that these animals have a compromised glutamate clearance when a challenging condition was presented. These results correlate with a hippocampal upregulation of the minor isoform of the Glt-1 gene, named Glt-1b, which has been associated with compensatory mechanisms activated in response to neuronal stress. In conclusion, the hippocampus of Epm2b-/- mice presents an in vivo impairment in glutamate uptake which could contribute to epileptogenesis., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2014-54604-C3-1-R, SAF2017-83151-R (to P.S.) and SAF2015-68346-P (to F.A.), co-funded by the European Regional Development Fund “A way to build Europe” (to F.A.), a grant from Fundación Ramón Areces (CIVP18A3935) and a grant from the National Institute of Health (NIH-NINDS) P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S. The Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and de Enfermedades Raras (CIBERER) are also acknowledged for financial support. We also thank Letizia Campa and Verónica Paz for their outstanding technical assistance. C.M.-B. holds a FPU fellowship from the Spanish Ministry of Education, Culture and Sports., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modulation of thalamo-cortical activity by the NMDA receptor antagonists ketamine and phencyclidine in the awake freely-moving rat

  • Amat Foraster, María
  • Celada, Pau
  • Richter, Ulrike
  • Jensen, Anders A.
  • Plath, Niels
  • Artigas, Francesc
  • Herrik, Kjartan F.
Non-competitive N-methyl-D-aspartate receptor antagonists mimic schizophrenia symptoms and produce immediate and persistent antidepressant effects. We investigated the effects of ketamine and phencyclidine (PCP) on thalamo-cortical network activity in awake, freely-moving male Wistar rats to gain new insight into the neuronal populations and brain circuits involved in the effects of NMDA-R antagonists. Single unit and local field potential (LFP) recordings were conducted in mediodorsal/centromedial thalamus and in medial prefrontal cortex (mPFC) using microelectrode arrays. Ketamine and PCP moderately increased the discharge rates of principal neurons in both areas while not attenuating the discharge of mPFC GABAergic interneurons. They also strongly affected LFP activity, reducing beta power and increasing that of gamma and high-frequency oscillation bands. These effects were short-lasting following the rapid pharmacokinetic profile of the drugs, and consequently were not present at 24 h after ketamine administration. The temporal profile of both drugs was remarkably different, with ketamine effects peaking earlier than PCP effects. Although this study is compatible with the glutamate hypothesis for fast-acting antidepressant action, it does not support a local disinhibition mechanism as the source for the increased pyramidal neuron activity in mPFC. The short-lasting increase in thalamo-cortical activity is likely associated with the rapid psychotomimetic action of both agents but could also be part of a cascade of events ultimately leading to the persistent antidepressant effects of ketamine. Changes in spectral contents of high-frequency bands by the drugs show potential as translational biomarkers for target engagement of NMDA-R modulators., The work leading to these results has received funding from Lundbeck A/S, the Innovation Fund Denmark and SAF2015-68346-P (Spanish Ministry of Economy and Competitiveness, co-financed by European Regional Development Fund (ERDF)) and PI12/00156 and PI16/00287 Instituto de Salud Carlos III, co-financed by European Regional Development Fund (ERDF)). Support from the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Generalitat de Catalunya Grup de Recerca Consolidat, 2017SGR717 is also acknowledged. Ulrike Richter is funded by Sweden's Innovation Agency VINNOVA.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptors

  • Riga, Maurizio
  • Lladó-Pelfort, Laia
  • Artigas, Francesc
  • Celada, Pau
5-MeO-DMT is a natural hallucinogen acting as serotonin 5-HT/5-HT receptor agonist. Its ability to evoke hallucinations could be used to study the neurobiology of psychotic symptoms and to identify new treatment targets. Moreover, recent studies revealed the therapeutic potential of serotonin hallucinogens in treating mood and anxiety disorders. Our previous results in anesthetized animals show that 5-MeO-DMT alters cortical activity via 5-HT and 5-HT receptors. Here, we examined 5-MeO-DMT effects on oscillatory activity in prefrontal (PFC) and visual (V1) cortices, and in mediodorsal thalamus (MD) of freely-moving wild-type (WT) and 5-HT-R knockout (KO2A) mice. We performed local field potential multi-recordings evaluating the power at different frequency bands and coherence between areas. We also examined the prevention of 5-MeO-DMT effects by the 5-HT-R antagonist WAY-100635. 5-MeO-DMT affected oscillatory activity more in cortical than in thalamic areas. More marked effects were observed in delta power in V1 of KO2A mice. 5-MeO-DMT increased beta band coherence between all examined areas. In KO2A mice, WAY100635 prevented most of 5-MeO-DMT effects on oscillatory activity. The present results indicate that hallucinatory activity of 5-MeO-DMT is likely mediated by simultaneous alteration of prefrontal and visual activities. The prevention of these effects by WAY-100635 in KO2A mice supports the potential usefulness of 5-HT receptor antagonists to treat visual hallucinations. 5-MeO-DMT effects on PFC theta activity and cortico-thalamic coherence may be related to its antidepressant activity. This article is part of the Special Issue entitled ‘Psychedelics: New Doors, Altered Perceptions’., This work was supported by grants from Instituto de Salud Carlos III (PI09/01245, PI12/00156 and PI16/00287 (PN de I + D + I 2008–2011, ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, Spanish Ministry of Economy and Competitiveness cofinanced by the European Regional Development Fund. “Una manera de hacer Europa”), and by grant SAF2015-68346-P (MINECO, FEDER EU) Centro de Investigación Biomédica en Red de Salud Mental, (CIBERSAM P82, 11INT3. Support from the Generalitat de Catalunya (2014 SGR798) is also acknowledged. MR was supported by an IDIBAPS fellowship.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In vivo knockdown of astroglial glutamate transporters GLT-1 and GLAST increases excitatory neurotransmission in mouse infralimbic cortex: Relevance for depressive-like phenotypes, GLT-1/GLAST knockdown and neuronal activity

  • Fullana, Neus
  • Covelo, Ana
  • Bortolozzi, Analía
  • Araque, Alfonso
  • Artigas, Francesc
Alterations of energy metabolism and of astrocyte number/function in ventral anterior cingulate cortex (vACC) have been reported in major depressive disorder (MDD) patients and may contribute to MDD pathophysiology. We recently developed a mouse model of MDD mimicking these alterations. We knocked down the astroglial glutamate transporters GLAST and GLT-1 in infralimbic cortex (IL, rodent equivalent of vACC) using small interfering RNA (siRNA). GLAST and GLT-1 siRNA microinfusion in IL evoked a depressive-like phenotype, associated with a reduced serotonergic function and reduced forebrain BDNF expression. Neither effect occurred after siRNA application in the adjacent prelimbic cortex (PrL), thus emphasizing the critical role of vACC/IL in MDD pathogenesis. Here we examined the cellular/network basis of the changes induced in IL using intracellular recordings of layer V pyramidal neurons from mice microinjected with siRNA 24 h before. We analyzed (i) the electrophysiological characteristics of neurons; (ii) the synaptic transmission properties, by monitoring miniature, spontaneous and evoked EPSCs, and (iii) the gliotransmission, by monitoring slow inward currents (SICs), mediated by astrocytic glutamate release and activation of extra-synaptic NMDA receptors. GLT-1 and GLAST knockdown led to a more depolarized membrane potential and increased action potential firing rate of layer V pyramidal neurons, and enhanced excitatory synaptic transmission, as shown by the enhanced amplitude/frequency of spontaneous EPSCs. Gliotransmission was also increased, as indicated by the enhanced SIC amplitude/frequency. Hence, the depressive-like phenotype is associated with IL hyperactivity, likely leading to an excessive top-down inhibitory control of serotonergic activity through IL-midbrain descending pathways., This work was supported by the Spanish Ministry of Economy and Competitiveness (grant numbers SAF2015-68346 to F.A., SAF2016-75797-R to A.B.), co-financed by European Regional Development Fund (ERDF) and NIH-NINDS (R01NS097312-01) and Human Frontier Science Program (Research Grant RGP0036/2014) to AA. The Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and CERCA Programme/Generalitat de Catalunya are also acknowledged. N.F. is a recipient of a fellowship from Spanish Ministry of Education, Culture and Sport.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Astrocyte control of glutamatergic activity: Downstream effects on serotonergic function and emotional behavior

  • Fullana, Neus
  • Gasull-Camós, Júlia
  • Tarrés-Gatius, Mireia
  • Castañé, Anna
  • Bortolozzi, Analía
  • Artigas, Francesc
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a poorly known pathophysiology and sub-optimal treatment, based on serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors. We review existing theories on MDD, paying special attention to the role played by the ventral anterior cingulate cortex (vACC) or its rodent equivalent, infralimbic cortex (IL), which tightly control the activity of brainstem monoamine neurons (including raphe 5-HT neurons) via descending afferents. Further, astrocytes regulate excitatory synapse activity via glutamate reuptake through astrocytic transporters EAAT1 and EAAT2 (GLAST and GLT-1 in rodents), and alterations of astrocyte number/function have been reported in MDD patients and suicide victims. We recently assessed the impact of reducing GLAST/GLT-1 function in IL on emotional behavior and serotonergic function in rodents. The acute pharmacological blockade of GLT-1 with dihydrokainate (DHK) in rat IL evoked an antidepressant-like effect mediated by local AMPA-R activation and a subsequent enhancement of serotonergic function. No effects were produced by DHK microinfusion in prelimbic cortex (PrL). In the second model, a moderate small interfering RNAs (siRNA)-induced reduction of GLAST and GLT-1 expression in mouse IL markedly increased local glutamatergic neurotransmission and evoked a depressive-like phenotype (reversed by citalopram and ketamine), and reduced serotonergic function and BDNF expression in cortical/hippocampal areas. As for DHK, siRNA microinfusion in PrL did not evoke behavioral/neurochemical effects. Overall, both studies support a critical role of the astrocyte-neuron communication in the control of excitatory neurotransmission in IL, and subsequently, on emotional behavior, via the downstream associated changes on serotonergic function., This study was supported by the Spanish Ministry of Economy and Competitiveness, SAF2015-68346-P MINECO/FEDER, UE (F.A.) and SAF2016-75797-R AEI/FEDER, UE (A.B.) co-financed by the European Regional Development Fund “A way to build Europe”. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and CERCA Programme/Generalitat de Catalunya is also acknowledged. The authors would also like to thank the support of the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (2017SGR717). N.F. was a recipient of a fellowship from Spanish Ministry of Education, Culture, and Sport. J.G-C was a recipient of a fellowship from the Spanish Ministry of Economy and Competitiveness (BES-2013-063241). M.T-G was a recipient of a fellowship from Generalitat de Catalunya (2016FI_B 00285) co-financed by the European Social Fund., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Serotonin receptors: Implications for depression and its treatment

  • Castañé, Anna
  • Artigas, Francesc
Trabajo presentado en el 14th World Congress of Biological Psychiatry, celebrado en Vancouver (Canadá), del 2 al 6 de junio de 2019, Objective: Major depressive disorder (MDD) is a psychiatric syndrome with a high socioeconomic impact, due to its high prevalence and to the limited efficacy of treatments. Antidepressant efficacy depends, to a large extent, on the synaptic availability of serotonin (5-hydroxytryptamine; 5-HT) even for fast-acting strategies such as ketamine. However, blockade of the 5-HT transporter (SERT), as evoked by most antidepressant drugs (TCAs, SSRI, SNRI, etc.) is insufficient by itself to improve symptoms in many patients. The aim of the present talk is to describe the principal serotonergic mechanisms that facilitate or slow the antidepressant response., Support from SAF2015-68346-P is acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Involvement of NMDA receptors containing the GluN2C subunit in the psychotomimetic and antidepressant-like effects of ketamine

  • Tarrés-Gatius, Mireia
  • Miquel-Rio, Lluís
  • Campa, Leticia
  • Artigas, Francesc
  • Castañé, Anna
Acute ketamine administration evokes rapid and sustained antidepressant effects in treatment-resistant patients. However, ketamine also produces transient perceptual disturbances similarly to those evoked by other non-competitive NMDA-R antagonists like phencyclidine (PCP). Although the brain networks involved in both ketamine actions are not fully understood, PCP and ketamine activate thalamo-cortical networks after NMDA-R blockade in GABAergic neurons of the reticular thalamic nucleus (RtN). Given the involvement of thalamo-cortical networks in processing sensory information, these networks may underlie psychotomimetic action. Since the GluN2C subunit is densely expressed in the thalamus, including the RtN, we examined the dependence of psychotomimetic and antidepressant-like actions of ketamine on the presence of GluN2C subunits, using wild-type and GluN2C knockout (GluN2CKO) mice. Likewise, since few studies have investigated ketamine’s effects in females, we used mice of both sexes. GluN2C deletion dramatically reduced stereotyped (circling) behavior induced by ketamine in male and female mice, while the antidepressant-like effect was fully preserved in both genotypes and sexes. Despite ketamine appeared to induce similar effects in both sexes, some neurobiological differences were observed between male and female mice regarding c-fos expression in thalamic nuclei and cerebellum, and glutamate surge in prefrontal cortex. In conclusion, the GluN2C subunit may discriminate between antidepressant-like and psychotomimetic actions of ketamine. Further, the abundant presence of GluN2C subunits in the cerebellum and the improved motor coordination of GluN2CKO mice after ketamine treatment suggest the involvement of cerebellar NMDA-Rs in some behavioral actions of ketamine., This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2015-68346-P and PI16/00287) co-financed by European Regional Development Fund; Generalitat de Catalunya (CERCA Program; 2014-SGR798; 2017-SGR717; 2016FI-B00285 to M.T.-G., co-financed by the European Social Fund); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brain circuitry in major depressive disorder: The critical role of ventral anterior cingulate cortex

  • Artigas, Francesc
Major Depressive Disorder (MDD) is a mood disorder characterized by a large number and variety of symptoms, including affective/emotional (persistent sadness, anhedonia, anxiety, agitation, guilt feelings, hopelessness, etc.), somatic (tiredness, loss of energy, sleep disturbances, reduced/increased appetite, weight gain/loss etc.) and cognitive symptoms (slowness of thinking, concentration difficulties, etc.). Overall, this suggests the presence of derangements of nerve transmission in different areas/circuits involved in the control of these disturbed brain functions., Supported by the Spanish Ministry of Economy and Competitiveness, SAF2015–68346-P MINECO/FEDER, co-financed by the European Regional Development Fund “A way to build Europe”. Supported also by the Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and by CERCA Programme from the Generalitat de Catalunya. I also would like to thank the support of the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya (2017SGR717)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discrimination of motor and sensorimotor effects of phencyclidine and MK-801: Involvement of GluN2C-containing NMDA receptors in psychosis-like models

  • Tarrés-Gatius, Mireia
  • López-Hill, Ximena
  • Miquel-Rio, Lluís
  • Castarlenas, Laura
  • Fabius, Sara
  • Santana, Noemí
  • Vilaró, Maria Teresa
  • Artigas, Francesc
  • Scorza, María Cecilia
Non-competitive NMDA receptor (NMDA-R) antagonists like ketamine, phencyclidine (PCP) and MK-801 are routinely used as pharmacological models of schizophrenia. However, the NMDA-R subtypes, neuronal types (e.g., GABA vs. glutamatergic neurons) and brain regions involved in psychotomimetic actions are not fully understood. PCP activates thalamo-cortical circuits after NMDA-R blockade in reticular thalamic GABAergic neurons. GluN2C subunits are densely expressed in thalamus and cerebellum. Therefore, we examined their involvement in the behavioral and functional effects elicited by PCP and MK-801 using GluN2C knockout (GluN2CKO) and wild-type mice, under the working hypothesis that psychotomimetic effects should be attenuated in mutant mice. PCP and MK-801 induced a disorganized and meandered hyperlocomotion in both genotypes. Interestingly, stereotyped behaviors like circling/rotation, rearings and ataxia signs were dramatically reduced in GluN2CKO mice, indicating a better motor coordination in absence of GluN2C subunits. In contrast, other motor or sensorimotor (pre-pulse inhibition of the startle response) aspects of the behavioral syndrome remained unaltered by GluN2C deletion. PCP and MK-801 evoked a general pattern of c-fos activation in mouse brain (including thalamo-cortical networks) but not in the cerebellum, where they markedly reduced c-fos expression, with significant genotype differences paralleling those in motor coordination. Finally, resting-state fMRI showed an enhanced cortico-thalamic-cerebellar connectivity in GluN2CKO mice, less affected by MK-801 than controls. Hence, the GluN2C subunit allows the dissection of the behavioral alterations induced by PCP and MK-801, showing that some motor effects (in particular, motor incoordination), but not deficits in sensorimotor gating, likely depend on GluN2C-containing NMDA-R blockade in cerebellar circuits., This work was supported by the Spanish Ministry of Economy and Competitiveness (grant numbers SAF2015-68346-P, PI16/00287) co-financed by European Regional Development Fund; Generalitat de Catalunya (CERCA Programme, grant numbers 2014-SGR798, 2017-SGR717, 2016FI-B00285 to M.T-G, co-financed by the European Social Fund); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM); and the Programa de Desarrollo de Ciencias Básicas (PEDECIBA-Uruguay).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preferential in vivo inhibitory action of serotonin in rat infralimbic versus prelimbic cortex: relevance for antidepressant treatments

  • López-Terrones, Elena
  • Celada, Pau
  • Riga, Maurizio
  • Artigas, Francesc
The infralimbic (IL) cortex is the rodent equivalent of human ventral anterior cingulate cortex (vACC), which plays a key role in the pathophysiology and treatment of major depressive disorder (MDD). The modulation of glutamatergic neurotransmission in IL [but not in the adjacent prelimbic (PrL) cortex] evokes antidepressant-like or depressive-like behaviors, associated with changes in serotonin (5-HT) function, highlighting the relevance of glutamate/serotonin interactions in IL for emotional control. 5-HT modulates neuronal activity in PrL and cingulate (Cg) cortex but its effects in IL are largely unknown. We therefore compared the in vivo effects of 5-HT on pyramidal neuron activity in IL (n = 61) and PrL (n = 50) of anesthetized rats. IL pyramidal neurons were more responsive to physiological dorsal raphe stimulation (0.9 Hz) than PrL neurons (84% vs. 64%, respectively) and were inhibited to a greater extent (64% vs. 36%, respectively). Orthodromic activations (8% in PrL) were absent in IL, whereas biphasic responses were similar (20%) in both areas. Excitations were mediated by 5-HT2A-R activation, whereas inhibitions involved 3 different components: 5-HT1A-R, 5-HT3-R and GABAA-R, respectively. The remarkable inhibitory action of 5-HT in IL suggests that 5-HT-enhancing drugs may exert their antidepressant action by normalizing a glutamatergic hyperactivity in the vACC of MDD patients., Spanish Ministry of Economy and Competitiveness (SAF2015-68346-P MINECO/FEDER, UE to F.A., PI16/00287 to P.C.; European Regional Development Fund “A way to build Europe.”; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM);CERCA Programme from the Generalitat de Catalunya. The authors of this study would like to thank the support of the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (2017SGR717). E.L.T. is recipient of a predoctoral contract from Spanish MINECO
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Differential Modulation of Dorsal Raphe Serotonergic Activity in Rat Brain by the Infralimbic and Prelimbic Cortices

  • López-Terrones, Elena
  • Paz, Verónica
  • Campa, Leticia
  • Conde-Berriozabal, Sara
  • Masana, Mercè
  • Artigas, Francesc
  • Riga, Maurizio
The reciprocal connectivity between the medial prefrontal cortex (mPFC) and the dorsal raphe nucleus (DR) is involved in mood control and resilience to stress. The infralimbic subdivision (IL) of the mPFC is the rodent equivalent of the ventral anterior cingulate cortex, which is intimately related to the pathophysiology/treatment of major depressive disorder (MDD). Boosting excitatory neurotransmission in the IL-but not in the prelimbic cortex, PrL-evokes depressive-like or antidepressant-like behaviors in rodents, which are associated with changes in serotonergic (5-HT) neurotransmission. We therefore examined the control of 5-HT activity by both of the mPFC subdivisions in anesthetized rats. The electrical stimulation of IL and PrL at 0.9 Hz comparably inhibited 5-HT neurons (53% vs. 48%, respectively). However, stimulation at higher frequencies (10-20 Hz) revealed a greater proportion of 5-HT neurons sensitive to IL than to PrL stimulation (86% vs. 59%, at 20 Hz, respectively), together with a differential involvement of GABAA (but not 5-HT1A) receptors. Likewise, electrical and optogenetic stimulation of IL and PrL enhanced 5-HT release in DR in a frequency-dependent manner, with greater elevations after IL stimulation at 20 Hz. Hence, IL and PrL differentially control serotonergic activity, with an apparent superior role of IL, an observation that may help to clarify the brain circuits involved in MDD., Supported by the Spanish Ministry of Economy and Competitiveness (SAF2015-68346-P MINECO/FEDER, UE to F.A.) and by the Spanish Ministry of Sciences, Innovation, and Universities (PID2021-124896OA-I00 to MM); European Regional Development Fund “A way to build Europe”; Instituto de Salud Carlos III (PI16/00287 to Pau Celada.), Centro de Investigaciones Biomédicas en Red de Salud Mental (CIBERSAM); CERCA Program from the Generalitat de Catalunya. This research is part of NEUROPA. The NEUROPA Project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 863214 to MM. The authors of this study would like to thank the support of the Secretaria d’Universitats I Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (2017SGR717). E.L.-T. is a recipient of a predoctoral contract from the Spanish MINECO., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Neurobiological mechanisms involved in the antidepressant and psychotomimetic effects of NMDA receptor antagonists: role of the GluN2C subunit

  • Tarrés-Gatius, Mireia
Tesis doctoral presentada para lograr el título de Doctor por la Universidad de Barcelona, Facultad de Medicina y Ciencias de la Salud.--Calificación: Sobresaliente cum lauden, [EN] Sub-anesthetic doses of ketamine evoke rapid and persistent antidepressant effects in treatment-resistant depressed patients through still poorly-known mechanisms. Ketamine also evokes transient psychotomimetic effects, shared by other non-competitive NMDA-R antagonists such as phencyclidine (PCP) and dizocilpine (MK-801), which are used as pharmacological models of schizophrenia. Previous studies indicate that PCP activates thalamo- cortical circuits after the blockade of NMDA-R in GABAergic neurons of the reticular nucleus (RtN). Given that one of the sites of action of non-competitive NMDA-R antagonists is the RtN and that the GluN2C subunit is expressed in this nucleus, our working hypothesis was that the psychotomimetic and the antidepressant-like effects induced by non-competitive NMDA-R antagonists would be partly attenuated in absence of the GluN2C subunit. All three NMDA-R antagonists induced psychotomimetic effects in both genotypes. While locomotor activity was increased in GluN2CKO mice, stereotyped behaviors like circling and ataxia signs (falls, hindlimb abduction) were dramatically attenuated, suggesting a better motor coordination in absence of the GluN2C subunit. In agreement, GluN2CKO mice spent more time on the rotarod compared to WT mice after PCP or MK-801 administration. However, there were no genotype differences in the PPI test, showing that the GluN2C subunit is not involved in sensory gating. Moreover, PCP and MK-801 evoked a general pattern of c-fos activation, except in cerebellum, where significant reductions and genotype differences were noted. Ketamine reduced the immobility time in male and female WT and GluN2CKO mice in tests used for the screening of antidepressants, showing that the GluN2C subunit does not contribute to the antidepressant-like effects induced by ketamine in both sexes. This acute antidepressant-like effect might be mediated by a transient increase of serotonin, but not glutamate, in the medial prefrontal cortex. Moreover, ketamine increased c-fos expression in the thalamus of female but not male mice, while reductions were only present in the cerebellum of male mice, suggesting sex-differentiated effects of ketamine. Regarding NMDA-R subunits distribution, deletion of the GluN2C subunit led to minor changes in the expression of GluN2A, GluN2B or GluN2D subunits, suggesting that it was not systematically replaced by any other GluN2 subunits. However, it produced remarkable changes in the expression of the GluN1 subunit in cerebellar and thalamic areas, which may contribute to the behavioral and molecular differences between both genotypes. In conclusion, the GluN2C subunit appears to be strongly involved in motor components of the behavioral syndrome induced by non-competitive NMDA-R antagonists, while the antidepressant-like effects of ketamine are preserved. Its genetic deletion results in an improved motor coordination after NMDA-R blockade. This supports the presence of GluN2C‐containing NMDA‐R in cerebellar circuits controlling motor activity and equilibrium, which are sensitive to the action of ketamine, PCP, and MK-801. Overall, the present study supports the involvement of cerebellar GluN2C subunits as a key element in the psychotomimetic actions of non- competitive NMDA-R antagonists. The differential role of the GluN2C subunit in mediating the psychotomimetic and antidepressant effects of ketamine identifies this subunit as a potential target for preventing the emergence of pro-psychotic effects while keeping a full antidepressant action., [ES] La ketamina, la fenciclidina (PCP) y la dizocilpina (MK-801) son antagonistas no competitivos del receptor NMDA y se utilizan como modelos farmacológicos de esquizofrenia ya que su administración evoca unos síntomas parecidos a los de un estado psicótico. Además, la ketamina también ejerce un efecto antidepresivo rápido y sostenido en el tiempo en pacientes depresivos resistentes a los tratamientos convencionales. Estudios previos han demostrado que PCP actuaría preferencialmente sobre neuronas GABAérgicas del núcleo reticular del tálamo, bloqueando su efecto inhibidor y, en consecuencia, activando circuitos tálamo-corticales. Dado que la subunidad GluN2C del NMDA-R se expresa en dicho núcleo talámico, en esta tesis hemos estudiado la posible implicación de la subunidad GluN2C en los efectos psicotomiméticos y antidepresivos inducidos por los antagonistas no competitivos del NMDA-R, bajo la hipótesis de trabajo de que estos efectos serían menores en ausencia de dicha subunidad. El tratamiento agudo con MK-801, PCP y ketamina indujo efectos psicotomiméticos en ratones WT y GluN2CKO. No obstante, la intensidad de las rotaciones (movimiento estereotipado), el número de caídas y el arrastrado de patas traseras (signos de ataxia) fueron significativamente menores en los ratones GluN2CKO, sugiriendo una mejor coordinación motora en ausencia de la subunidad GluN2C. De acuerdo con estos resultados, en los ratones GluN2CKO observamos un mayor tiempo de permanencia en el rotarod en comparación con los ratones WT tras la administración aguda de MK-801 o PCP. Sin embargo, no encontramos diferencias de genotipo en el test de la inhibición pre-pulso, sugiriendo que la subunidad GluN2C no estaría relacionada con la regulación sensoriomotora. La administración de MK-801 y PCP provocó un aumento generalizado de la expresión del gen c-fos en el cerebro de los ratones WT y GluN2CKO, excepto en el cerebelo, dónde se observaron reducciones y diferencias de genotipo en su expresión. Respecto a los efectos antidepresivos, ketamina redujo el tiempo de inmovilidad en machos y hembras WT y GluN2CKO, sugiriendo que la subunidad GluN2C no está involucrada en la acción antidepresiva de ketamina. Además, ketamina aumentó la liberación de serotonina en la corteza prefrontal en ambos géneros, sugiriendo que el efecto antidepresivo podría estar relacionado con este neurotransmisor. En comparación con MK-801 y PCP, el patrón de expresión de c-fos después de la administración de ketamina no fue tan intenso y se observaron diferencias de género. En conclusión, este trabajo demuestra que existe una disociación en cuanto a la participación de la subunidad GluN2C en los efectos motores y el efecto antidepresivo inducidos por antagonistas no competitivos del NMDA-R. Debido a que la subunidad GluN2C se encuentra altamente expresada en el cerebelo y que ésta es un área involucrada en coordinación motora, los NMDA-R de cerebelo podrían jugar un papel importante en el mecanismo de acción de MK-801, PCP y ketamina.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lu AF35700 reverses the phencyclidine-induced disruption of thalamo-cortical activity by blocking dopamine D1 and D2 receptors

  • Riga, Maurizio
  • Paz, Veronica
  • Didriksen, Michael
  • Celada, Pau
  • Artigas, Francesc
Antipsychotic drugs of different chemical/pharmacological families show preferential dopamine (DA) D2 receptor (D2-R) vs. D1 receptor (D1-R) affinity, with the exception of clozapine, the gold standard of schizophrenia treatment, which shows a comparable affinity for both DA receptors. Here, we examined the ability of Lu AF35700 (preferential D1-R>D2-R antagonist), to reverse the alterations in thalamo-cortical activity induced by phencyclidine (PCP), used as a pharmacological model of schizophrenia. Lu AF35700 reversed the PCP-induced alteration of neuronal discharge and low frequency oscillation (LFO, 0.15-4 Hz) in thalamo-cortical networks. Likewise, Lu AF35700 prevented the increased c-fos mRNA expression induced by PCP in thalamo-cortical regions of awake rats. We next examined the contribution of D1-R and D2-R to the antipsychotic reversal of PCP effects. The D2-R antagonist haloperidol reversed PCP effects on thalamic discharge rate and LFO. Remarkably, the combination of sub-effective doses of haloperidol and SCH-23390 (DA D1-R antagonist) fully reversed the PCP-induced fall in thalamo-cortical LFO. However, unlike with haloperidol, SCH-23390 elicited different degrees of potentiation of the effects of low clozapine and Lu AF35700 doses. Overall, the present data support a synergistic interaction between both DA receptors to reverse the PCP-induced alterations of oscillatory activity in thalamo-cortical networks, possibly due to their simultaneous blockade in direct and indirect pathways of basal ganglia. The mild potentiation induced by SCH-23390 in the case of clozapine and Lu AF35700 suggests that, at effective doses, these agents reverse PCP effects through the simultaneous blockade of both DA receptors., Funding for this study was provided by Lundbeck A/S and grants: SAF2015-68346-P (Spanish Ministry of Economy and Competitiveness, co-financed by European Regional Development Fund (ERDF)) and PI16/00287 (Instituto de Salud Carlos III, also co-financed by ERDF). Support from the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Generalitat de Catalunya Grup de Recerca Consolidat, 2017SGR717 is also acknowledged. All of them had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Serotonergic mechanisms involved in antidepressant-like responses evoked by GLT-1 blockade in rat infralimbic cortex

  • Gasull-Camós, Júlia
  • Martínez-Torres, Sara
  • Tarrés-Gatius, Mireia
  • Ozaita Mintegui, Andrés, 1969-
  • Artigas, Francesc
  • Castañé Forn, Anna
Novel fast-acting antidepressant strategies, such as ketamine and deep brain stimulation, enhance glutamatergic neurotransmission in medial prefrontal cortex (mPFC) regions via AMPA receptor (AMPA-R) activation. We recently reported that the regionally-selective blockade of the glial glutamate transporter-1 (GLT-1) by dihydrokainic acid (DHK) microinfusion in rat infralimbic cortex (IL), the most ventral part of the mPFC, evoked immediate (10 min) antidepressant-like responses, which involved AMPA-R activation and were associated to increased serotonin (5-hydroxytryptamine, 5-HT) release. Given the reciprocal connectivity between the mPFC and the serotonergic dorsal raphe nucleus (DR), here we examined the serotoninergic mechanisms involved in the reported antidepressant-like responses of DHK microinfusion. First, we show that antidepressant-like responses evoked by IL application of DHK and citalopram are mediated by local 5-HT1A receptors (5-HT1A-R), since they are cancelled by previous IL WAY100635 microinfusion. Second, IL DHK microinfusion increases excitatory inputs onto DR, as shown by an increased glutamate and 5-HT release in DR and by a selective increase of c-Fos expression in DR 5-HT neurons, not occurring in putative GABAergic neurons. This view is also supported by an increased 5-HT release in ventral hippocampus following IL DHK microinfusion. Interestingly, antidepressant-like responses evoked by IL DHK lasted for 2¿h and could be prolonged for up to 24¿h by attenuating self-inhibitory effects via 5-HT1A autoreceptors. In contrast, the antidepressant-like effects of S-AMPA microinfusion in IL were short-lasting. Together, our results further support a prominent role of the IL-DR pathway and of ascending 5-HT pathways in mediating antidepressant-like responses evoked by glutamatergic mechanisms., This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2015-68346 and BES2013-063241 to J.G-C; BFU2015-68568-P to A.O.) co-financed by European Regional Development Fund; Generalitat de Catalunya (CERCA Programme; 2014-SGR798, 2016FI-B00285 to M.T-G, 2016 FI-B00531 to S.M-T and ICREA Acadèmia to A.O.); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM).